试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-02
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
编号:NCT05071183登记状态:提前终止企业 / 申办者:Turning Point Therapeutics, Inc.
药物 / 成分:TPX-0005、Trametinib
登记的停止原因(原文):Inability to achieve and optimize a dose that could provide a positive benefit risk profile
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-02
Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)
编号:NCT05162027登记状态:提前终止企业 / 申办者:University of Maryland, Baltimore
药物 / 成分:Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe、Placebo
登记的停止原因(原文):Low enrollment rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-02
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
编号:NCT05667662登记状态:提前终止企业 / 申办者:Pulmatrix Inc.
药物 / 成分:Itraconazole Powder、Placebo
登记的停止原因(原文):Low enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-02
Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.
编号:NCT05687617登记状态:提前终止企业 / 申办者:Laval University
药物 / 成分:Indocyanine green
登记的停止原因(原文):Recruitment lower than expected and negative results.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-29
A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients
编号:NCT02446145登记状态:提前终止企业 / 申办者:Technische Universität Dresden
药物 / 成分:Eltrombopag、Placebo
登记的停止原因(原文):Due to COVID-19 pandemia, recruitment was insufficient to reach required sample size in an acceptable time line. Furthermore, new drugs have recently been licensed resulting in alternative treatment regimens with a better prognosis.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-29
A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout
编号:NCT05256810登记状态:提前终止企业 / 申办者:Alnylam Pharmaceuticals
药物 / 成分:ALN-XDH、Placebo
登记的停止原因(原文):The Sponsor elected not to continue with the study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-28
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
编号:NCT03288493登记状态:提前终止企业 / 申办者:Poseida Therapeutics, Inc.
药物 / 成分:P-BCMA-101 CAR-T cells、Rimiducid
登记的停止原因(原文):Phase I portion of the study was completed. The phase II portion of the study was terminated early to focus on an Allogeneic BCMA CAR-T program.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-28
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
编号:NCT04300114登记状态:提前终止企业 / 申办者:Jiangsu HengRui Medicine Co., Ltd.
药物 / 成分:Fluzoparib、Placebo
登记的停止原因(原文):Sponsor R \& D Strategy Adjustment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-28
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
编号:NCT04901806登记状态:提前终止企业 / 申办者:Pyramid Biosciences
药物 / 成分:PBI-200
登记的停止原因(原文):Sponsor terminated development of PBI-200
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-28
Estrogen (Gel)Transdermal vs Oral Estrogen for Endometrial Preparation
编号:NCT05802303登记状态:提前终止企业 / 申办者:Indira IVF Hospital Pvt Ltd
药物 / 成分:17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)、Estradiol Hemihydrate(Estrabet Tablet, abbott pharma)
登记的停止原因(原文):As per institutional protocol unable to recruit adequate number of patients
查看官方原始记录 ↗